Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-09-08 02:01 UTC

BIOMED PULSE

September 8, 2026 | Daily Briefing on Longevity, Viruses, and New Cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo has now spread to 60 health zones across 6 provinces, making it the largest Ebola outbreak ever recorded in DRC — a genuine historic emergency. Mood: grave on outbreak front, cautiously active on longevity science.

🦠 OUTBREAKS & VIRUSES

EBOLA (BUNDIBUGYO VIRUS) — DRC AND UGANDA: LARGEST OUTBREAK ON RECORD

  • As of August 28, 2026, the Bundibugyo virus disease (BVD) outbreak has reached 60 health zones, up from 54 in the previous WHO Disease Outbreak News report published August 14. [1]
  • Six of DRC's 26 provinces are now affected: Bas-Uele, Haut-Uele, Ituri, North Kivu, South Kivu, and Tshopo — six additional health zones were newly reported in the latest update. [1]
  • WHO characterized this as the largest Ebola outbreak ever reported in DRC and described it as expanding faster than any previous Ebola outbreak, driven by sustained community transmission. [2]
  • As of July 15, 2026, cumulative confirmed cases stood at 2,124 including 828 deaths — a case fatality rate above 39% among confirmed cases. [3]
  • Cross-border transmission to Uganda has been documented since at least May 15, when both the DRC Ministry of Public Health and Uganda's Ministry of Health declared the outbreak simultaneously. [4]
  • CDC has mobilized international response resources and began enhanced Ebola airport screening at Washington-Dulles International Airport on May 21, 2026, later expanding screening to Atlanta. [5] [6]

HANTAVIRUS (ANDES VIRUS) — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • The Andes hantavirus (ANDV) outbreak linked to the cruise ship M/V Hondius, first notified to WHO on May 2, 2026, remains under active monitoring as of the most recent WHO Disease Outbreak News (DON611, July 2, 2026). [7]
  • The fifth DON update confirmed additional confirmed cases since the previous report of May 28; the ship originally carried 147 passengers and crew with 34 having previously disembarked before detection. [7] [8]
  • Andes hantavirus causes hantavirus pulmonary syndrome, a severe acute respiratory illness; person-to-person transmission of ANDV is unusual among hantaviruses and has been documented in past South American clusters. [9]
  • CDC provided response transcripts on June 24, 2026, indicating ongoing monitoring of affected individuals across multiple countries. [10]

MEASLES — BANGLADESH

  • WHO notified on April 23, 2026 of a nationwide measles surge in Bangladesh, affecting 58 out of 64 districts across all 8 divisions, with 19,161 suspected cases and 2,897 laboratory-confirmed cases reported.
  • The outbreak spans the entire country geographically, underlining continued gaps in measles vaccination coverage in high-density populations.

NIPAH VIRUS — INDIA (KERALA)

  • On June 25, 2026, WHO published a Disease Outbreak News report confirming one laboratory-confirmed Nipah virus (NiV) infection in Kozhikode district, Kerala State, India.
  • The adult male case developed symptoms on May 30, 2026, was hospitalized June 10, and presented with neurological symptoms consistent with NiV encephalitis; Kozhikode has been the site of prior NiV outbreaks.

AVIAN INFLUENZA A(H9N2) — ITALY

  • On March 21, 2026, Italy's IHR Focal Point notified WHO of a human case of avian influenza A(H9N2) in an adult male returning from Senegal; next-generation sequencing confirmed the subtype.
  • H9N2 is a low-pathogenicity avian influenza strain with zoonotic potential; this case highlights travel-associated cross-border spillover risk.

CYCLOSPORIASIS — TACO BELL / ICEBERG LETTUCE

  • As of July 17, 2026, CDC identified shredded iceberg lettuce served at Taco Bell locations in five states as the source of a Cyclospora cayetanensis infection cluster, with 1,644 people sickened.
  • The outbreak subsequently expanded to four additional states by July 24, 2026.

SALMONELLA — METABOLIC MEALS HOME DELIVERY

  • As of September 5, 2026, CDC is investigating 16 Salmonella illnesses in 10 states linked to Metabolic Meals home-delivery food products, with an investigation still ongoing.

WEST NILE VIRUS — EARLY SEASON SURGE

  • CDC flagged an early and record-pace West Nile virus season as of July 1, 2026, urging mosquito bite prevention measures during the July 4 holiday weekend.

YELLOW FEVER — GLOBAL

  • WHO's DON610 (June 24, 2026) reported that from January 1 to May 26, 2026, six countries across Africa and the Americas reported a combined 79 human yellow fever infections, following elevated transmission in the Americas that carried over from 2025.

🧬 LONGEVITY & AGING

HEAT TOLERANCE AND AGING — GLOBAL PROJECTION STUDY

  • A Lancet Planetary Health modeling study projects that as both global temperatures and population age rise simultaneously, an increasing share of older adults will exceed human physiological heat-tolerance thresholds; older bodies lose thermoregulatory efficiency faster under heat stress.
  • The study by Kong, Vecellio, Huber and colleagues underscores that aging populations in tropical and subtropical regions face disproportionate future heat mortality risk.

TESTOSTERONE, LONGEVITY, AND REPRODUCTIVE TRADE-OFFS

  • A Mendelian randomization study published in Aging Male (Jiesisibieke and Schooling, August 17, 2026) investigates the evolutionary trade-off between testosterone's role in reproductive fitness and its potential costs to longevity, using genetic proxies to infer causal direction.
  • A separate international expert consensus paper in Aging Male (David, Burté, Byrne et al., August 26, 2026) addresses managing testosterone deficiency in primary care, noting underdiagnosis and offering standardized international guidance.

SENESCENCE TARGETING FOR DISC DEGENERATION

  • A Biomaterials study (Shi, Yang et al., July 14, 2026) reports engineered senescence-targeting apoptotic extracellular vesicles loaded into injectable hydrogel microspheres, designed to reduce ferroptosis — a form of iron-dependent cell death — in nucleus pulposus cells and thereby slow intervertebral disc degeneration.
  • The mechanism combines senolytic extracellular vesicles with a scaffold delivery system, representing a dual anti-aging / anti-ferroptosis approach for spinal aging.

OSTEOARTHRITIS SENESCENCE — DUAL ANTIOXIDANT AND EPIGENETIC STRATEGY

  • Researchers (An, Cai, Wu et al., Bioactive Materials, July 31, 2026) report a dual-modal treatment combining antioxidant and epigenetic modulation to break the self-perpetuating senescence cycle in osteoarthritis cartilage — targeting both reactive oxygen species and aberrant chromatin remodeling simultaneously.
  • Immune dysregulation in osteoarthritis, including T-cell and macrophage dysregulation, is examined in a separate J Translational Autoimmunity review (Enteshari-Moghaddam et al., August 20, 2026), identifying biomarkers and therapeutic targets.

BONE REPAIR AND AGING — mRNA LIPID NANOPARTICLE APPROACH

  • A Bioactive Materials study (Cheng, Xi et al., August 20, 2026) describes a dual-targeting mRNA lipid nanoparticle that restores ABCA1-dependent cholesterol homeostasis, promoting repair of age-related bone defects in preclinical models.
  • Loss of EGFR activity in skeletal stem/progenitor cells is independently reported (Hu, Wang et al., Bioactive Materials, August 4, 2026) as a key mechanism impairing fracture healing in aged mice, potentially explaining the clinical observation of slower fracture repair in older patients.

UROLITHIN A AND GLUCOSE METABOLISM IN OLDER ADULTS — TRIAL UPDATE

  • A randomized triple-masked controlled trial (NCT06274749) is evaluating urolithin A (UA) supplementation's effect on glucose metabolism in healthy adults aged 55 and older, recognizing that pancreatic beta-cell insulin secretion declines with age; the trial is listed as updated September 4, 2026 on ClinicalTrials.gov.
  • Urolithin A is a gut-microbiome-derived metabolite of ellagitannins that activates mitophagy — the cellular recycling of damaged mitochondria — a pathway implicated in aging and metabolic decline.

NICOTINAMIDE RIBOSIDE (NR) AND FATTY LIVER

  • Trial NCT06044935, updated September 4, 2026, is testing nicotinamide riboside — an NAD+ precursor — alongside a low-carbohydrate diet for effects on ketosis, fat oxidation, and metabolic rate in the context of fatty liver disease, noting that at least 30% of Americans have fatty liver.

DEMENTIA AND CANCER INCIDENCE — ECOLOGICAL ANALYSIS

  • A sex-specific ecological analysis in Future Science OA (You, Chang et al., September 4, 2026) examines relationships between dementia incidence and cancer incidence across countries, a line of research probing whether shared immune and metabolic pathways link these two major age-associated diseases.

DEPRESCRIBING IN OLDER ADULTS — FRAMEWORK DEBATE

  • Two Lancet Healthy Longevity commentaries (Hwang, Boockvar, Steinman; and Van der Linden, both July 8) argue that deprescribing trials in older adults need a rationale-first framework before selecting trial design, warning against polypharmacy continuation without rigorous re-evaluation of each drug's benefit-risk balance.

ANAESTHESIA FOR HIP FRACTURE IN OLDER PATIENTS — RCT

  • A multicentre randomized clinical trial from Germany (Kowark, Schoenen et al., Lancet Healthy Longevity, August 7, 2026) compares spinal versus general anaesthesia for hip fracture surgery in older patients, assessing serious complication rates — directly relevant to perioperative mortality risk in the elderly.

CARDIOMETABOLIC MULTIMORBIDITY, SLEEP, AND DEPRESSION IN AGING

  • A two-cohort longitudinal study in Journal of Affective Disorders (Zhang, Sun et al., August 21, 2026) finds associations between cardiometabolic multimorbidity combined with abnormal sleep duration and both onset and reversion of depressive symptoms, highlighting sleep as a modifiable factor in aging-related mental health trajectories.

💊 NEW CURES & APPROVALS

NOTE: The openFDA supplemental approval (SUPPL AP) items in today's data reflect labeling or manufacturing supplement actions rather than new molecular entity approvals; no new first-in-class or novel indication approvals with full details were present. Key recent supplement actions include:

  • KRAZATI (adagrasib), sponsor Bristol-Myers Squibb, received a supplemental approval (SUPPL AP) on NDA216340; adagrasib is a KRAS G12C inhibitor indicated for KRAS G12C-mutated non-small cell lung cancer and colorectal cancer.
  • CIBINQO (abrocitinib), sponsor Pfizer, received a supplemental approval on NDA213871; abrocitinib is a JAK1 inhibitor indicated for moderate-to-severe atopic dermatitis in adults.
  • FYARRO (sirolimus albumin-bound nanoparticles), sponsor AADI, received a supplemental approval on NDA213312; indicated for locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
  • BYOOVIZ (ranibizumab-nuna), sponsor Samsung Bioepis, received a supplemental approval on BLA761202; this is a ranibizumab biosimilar for neovascular age-related macular degeneration and related retinal conditions.
  • SHEUR (elagolix / estradiol / norethindrone acetate combination), sponsor Teva Pharmaceuticals, received an original tentative approval (ORIG TA) on ANDA217650; the combination is indicated for endometriosis-associated pain management.
  • DAPAGLIFLOZIN, sponsor Ajanta Pharma Ltd, received a supplemental approval on ANDA211482; dapagliflozin is an SGLT2 inhibitor used for type 2 diabetes, heart failure, and chronic kidney disease.

🧪 CLINICAL TRIALS

ALZHEIMER'S DISEASE PSYCHOSIS — KarXT (PHASE 3, ADEPT-2)

  • Trial NCT06126224 (ADEPT-2) is a Phase 3, randomized, double-blind, placebo-controlled study evaluating KarXT — a combination of xanomeline (an M1/M4 muscarinic receptor agonist) and trospium — for psychosis associated with Alzheimer's disease in patients aged 55–90 with mild-to-severe AD and moderate-to-severe psychosis.
  • KarXT targets cholinergic rather than dopaminergic pathways, a mechanistic departure from standard antipsychotics that may reduce metabolic and extrapyramidal side effects in elderly patients.

VENETOCLAX + ASTX727 FOR ELDERLY AML PATIENTS (PHASE II)

  • Trial NCT04746235 combines venetoclax (BCL-2 inhibitor) with ASTX727 (a cedazuridine/decitabine oral hypomethylating agent) for relapsed/refractory or newly diagnosed acute myeloid leukemia, specifically in elderly patients ineligible for intensive chemotherapy; the trial record was updated September 4, 2026.

UROLITHIN A IN ADULTS 55+ — GLUCOSE METABOLISM (RANDOMIZED TRIPLE-MASKED)

  • NCT06274749 (updated September 4, 2026) is a randomized triple-masked controlled trial testing urolithin A supplementation for its effect on glucose metabolism via mitophagy activation in adults 55 years and older.

NICOTINAMIDE RIBOSIDE — FATTY LIVER AND METABOLIC RATE

  • NCT06044935 (updated September 4, 2026) tests nicotinamide riboside, an NAD+ precursor, combined with low-carbohydrate diet to assess effects on ketosis, fat oxidation, and metabolic rate in people with fatty liver disease.

TILREKIMIG FOR MODERATE-TO-SEVERE ATOPIC DERMATITIS

  • NCT07765888 (updated September 4, 2026) studies tilrekimig — an investigational biologic — in combination with topical corticosteroids in adults and adolescents with moderate-to-severe atopic dermatitis (eczema), assessing efficacy and safety.

FOSTAMATINIB IN LUNG TRANSPLANT — SIMILAR TRIAL (SYK INHIBITION)

  • NCT06948097 (SIMILAR trial, updated September 4, 2026) evaluates the safety and tolerability of fostamatinib, a Syk (spleen tyrosine kinase) inhibitor, in lung transplant patients who have developed donor-specific antibodies — a leading cause of chronic lung allograft rejection.

TAPISTRY PLATFORM TRIAL — TUMOR-AGNOSTIC PRECISION ONCOLOGY (PHASE II)

  • NCT04589845 (TAPISTRY, updated September 4, 2026) is a Phase II global multicenter open-label multi-cohort platform trial evaluating targeted therapies and immunotherapy in patients with unresectable, locally advanced, or metastatic solid tumors identified by biomarker profiling — a tumor-agnostic design.

📢 PUBLIC HEALTH

DRUG-RESISTANT BACTERIA — SHARP RISE REPORTED

  • A CDC report released September 23, 2025 found a dramatic increase in a dangerous type of drug-resistant bacteria in the United States, underscoring the ongoing antimicrobial resistance threat to public health infrastructure.

CONGENITAL SYPHILIS — 12TH CONSECUTIVE YEAR OF INCREASE

  • New CDC data published September 24, 2025 show U.S. cases of syphilis in newborns (congenital syphilis) increased for the 12th consecutive year in 2024, signaling a continuing failure to interrupt vertical transmission.

LISTERIA — EXPANDED OUTBREAK IN PREPARED MEALS

  • CDC's ongoing Listeria monocytogenes outbreak linked to prepared meals was expanded on September 26, 2025 to include additional prepared food products, with 3 additional illnesses and 1 additional death newly reported.

SALMONELLA — MULTIPLE ACTIVE ALERTS

  • Sixteen people across 10 states are ill in an ongoing Salmonella outbreak tied to Metabolic Meals home-delivery foods, as of September 5, 2026.
  • CDC continues to warn about a previous outbreak now totaling 95 people in 14 states linked to recalled eggs.

CDC BIOSURVEILLANCE MILESTONE

  • CDC announced January 30, 2026 that its Traveler-Based Genomic Surveillance program surpassed 1 million voluntary air travel participants, a key tool for early detection of emerging pathogens at U.S. borders.

U.S. WHO WITHDRAWAL — CONTEXT

  • The United States completed its formal withdrawal from the World Health Organization on January 22, 2026, with WHO stating on January 24, 2026 that the decision "makes both the United States and the world less safe" — a structural gap in global health governance now operative during the largest Ebola outbreak in DRC history.

BIOMED PULSE is an informational digest compiled from official public sources. Nothing here constitutes medical advice. Consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus – Democratic Republic… — WHO Disease Outbreak News
  5. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  6. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  7. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  8. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  9. Hantavirus cluster linked to cruise ship travel, Multi-country — WHO Disease Outbreak News
  10. Transcript - Update on CDC's Hantavirus Response - 6/24/26 — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260908-02-v69 · 2026-09-08 02:01 UTC · pulse.uzylab.com

Read next